According to findings published in Science, researchers unveiled a unique vaccination strategy, which employs a staged method of creating antibodies capable of focusing on various HIV variants.

In the past, scientists tried but failed to create a vaccine to prevent HIV effectively. A novel vaccine design technique that exhibits new potential is being tested for the first time in a first-in-human clinical trial.

The first step of the multi-stage HIV vaccination regimen that researchers are developing was put to the test in the Phase 1 experiment, known as IAVI G001. To eventually develop bnAbs that can defend against HIV, the researchers employ a technique known as "germline targeting." The initial stage of germline targeting is activating the uncommon immune cells known as bnAb-precursor B cells, which can eventually develop into the cells that create the bnAbs required to stop the virus. An immunogen that would "prime" the immune system and elicit responses from these uncommon bnAb-precursor cells was created to complete this initial stage.

The study results demonstrate that the vaccination had a good safety profile and elicited the desired reaction in 97% of recipients. The Science study, which is significant, also offers a thorough immunological examination of the vaccine responses.

These results, according to the researchers, were very encouraging because they showed that the concepts of immunogen design could be applied to a wide variety of epitopes, whether for HIV or other diseases. With these encouraging results in hand spanning safety and immune responses, the researchers will continue to iterate and construct boosting immunogens to finally induce the required bnAbs and provide protection against the virus.

(Source: https://theprint.in/health/researchers-reveal-new-insights-into-novel-hiv-vaccine-strategy/1248627/)